



# Correction to: Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study

Sermsiri Sangroongruangsri<sup>1</sup> · Usa Chaikledkaew<sup>1</sup> · Suthasinee Kumluang<sup>2</sup> · Olivia Wu<sup>3</sup> · Claudia Geue<sup>3</sup> · Tanapat Ratanapakorn<sup>4</sup> · Pattara Leelahavarong<sup>2</sup> · Lily Ingsrisawang<sup>5</sup> · Paisan Ruamviboonsuk<sup>6</sup> · Wongsiri Taweebanjongsin<sup>7</sup> · Janejit Choovuthayakorn<sup>8</sup> · Apichart Singalavanija<sup>9</sup> · Prut Hanutsaha<sup>10</sup> · Kittisak Kulvichit<sup>11</sup> · Thitiporn Ratanapojnard<sup>12</sup> · Warapat Wongsawad<sup>7</sup> · Yot Teerawattananon<sup>2</sup>

Published online: 19 January 2019  
© The Author(s) 2019

## Correction to:

**Clinical Drug Investigation (2018) 38:853–865**  
<https://doi.org/10.1007/s40261-018-0678-5>

The Open Access license, which previously read:

## Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Should read:

## Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article has been corrected.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40261-018-0678-5>.

✉ Usa Chaikledkaew  
usa.chi@mahidol.ac.th

<sup>1</sup> Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, 447 Sri-Ayuthaya Road, Rajathevi, Bangkok 10400, Thailand

<sup>2</sup> Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand

<sup>3</sup> Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

<sup>4</sup> Department of Ophthalmology, Khon Kaen University, Khon Kaen, Thailand

<sup>5</sup> Department of Statistics, Faculty of Science, Kasetsart University, Bangkok, Thailand

<sup>6</sup> Department of Ophthalmology, Faculty of Medicine, Rajavithi Hospital, Rangsit University, Bangkok, Thailand

<sup>7</sup> Mettapracharak Eye Institute, Mettapracharak (Wat Rai Khing) Hospital, Nakhon Pathom, Thailand

<sup>8</sup> Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

<sup>9</sup> Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

<sup>10</sup> Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

<sup>11</sup> Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

<sup>12</sup> Department of Ophthalmology, Phramongkutklao Hospital, Phramongkutklao College of Medicine, Bangkok, Thailand